DSG Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

DSG Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$734K	Sell	1,540 -1,685	-52%	-$747K	0.1%	85
2026 Q1	$1.44M	Sell	3,225 -155	-5%	-$72.3K	0.23%	63
2025 Q4	$1.48M	Sell	3,380 -185	-5%	-$79.7K	0.23%	61
2025 Q3	$1.4M	Buy	3,565 +20	+0.6%	+$8.36K	0.22%	60
2025 Q2	$1.58M	Sell	3,545 -80	-2%	-$36.9K	0.28%	59
2025 Q1	$1.76M	Hold	3,625	–	–	0.36%	55
2024 Q4	$1.46M	Buy	+3,625	New	+$1.68M	0.26%	67

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DSG Capital Advisors's VRTX Position: Q2 2026 in Review

DSG Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 52% in Q2 2026, selling an estimated $747K and leaving 1,540 shares worth $734K. The position accounts for 0.1% of the portfolio, ranked #85.

DSG Capital Advisors first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.76M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

DSG Capital Advisors held 1,540 shares of Vertex Pharmaceuticals worth $734K as of Q2 2026.
DSG Capital Advisors sold 1,685 Vertex Pharmaceuticals shares in Q2 2026, an estimated $747K.
Vertex Pharmaceuticals made up 0.1% of DSG Capital Advisors's portfolio in Q2 2026, its #85 holding.
DSG Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
DSG Capital Advisors's Vertex Pharmaceuticals position peaked at $1.76M in Q1 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on DSG Capital Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.